Ignite Creation Date:
2024-05-05 @ 11:26 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00048633
Status:
COMPLETED
Last Update Posted:
2012-05-23
First Post:
2002-11-04
Brief Title:
Phase II Study to Evaluate Tariquidar XR9576 a Selective MDR-1 Inhibitor in Chemotherapy Resistant Advanced Breast Cancer
Sponsor:
QLT Inc
Organization:
QLT Inc
Study Overview
Official Title:
None
Status:
COMPLETED
Status Verified Date:
2012-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objective of this phase II study is to assess if XR9576 a selective MDR-1 inhibitor is able to reverse primary doxorubicin or taxane resistance in advanced breast cancer Clinical activity will be measured by objective tumor response rates observed after treatment with XR9576 in combination with taxane or anthracycline containing chemotherapy in patients previously resistant to the same agents
The secondary objectives of the study are to assess the biological activity of XR9576 and evaluate MDR-1 expression in these tumors The MDR-1 inhibitory activity of XR9576 will be evaluated by serial sestamibi scans of the tumor MDR-1 expression will be detected by immunohistochemistry
The secondary objectives of the study are to assess the biological activity of XR9576 and evaluate MDR-1 expression in these tumors The MDR-1 inhibitory activity of XR9576 will be evaluated by serial sestamibi scans of the tumor MDR-1 expression will be detected by immunohistochemistry
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None